{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:44:18Z","timestamp":1788281058394,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T00:00:00Z","timestamp":1475625600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["T32AR048522"],"award-info":[{"award-number":["T32AR048522"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Treat Options in Rheum"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s40674-016-0055-6","type":"journal-article","created":{"date-parts":[[2016,10,5]],"date-time":"2016-10-05T01:07:55Z","timestamp":1475629675000},"page":"271-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Osteoporosis Management in Ankylosing Spondylitis"],"prefix":"10.1007","volume":"2","author":[{"given":"Alicia M.","family":"Hinze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant H.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,5]]},"reference":[{"key":"55_CR1","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1007\/s00198-010-1338-7","volume":"22","author":"S Arends","year":"2011","unstructured":"Arends S, Spoorenberg A, Bruyn GA, Houtman PM, Leijsma MK, Kallenberg CGM, et al. The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int. 2011;22:1431\u20139. Available from: \n                      http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3073049&tool=pmcentrez&rendertype=abstract\n                      \n                    .","journal-title":"Osteoporos Int"},{"key":"55_CR2","first-page":"2205","volume":"26","author":"A El Maghraoui","year":"1999","unstructured":"El Maghraoui A, Borderie D, Cherruau B, Edouard R, Dougados M, Roux C. Osteoporosis, body composition, and bone turnover in ankylosing spondylitis. J Rheumatol. 1999;26:2205\u20139.","journal-title":"J Rheumatol"},{"key":"55_CR3","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s10067-010-1648-3","volume":"30","author":"L Muntean","year":"2011","unstructured":"Muntean L, Rojas-Vargas M, Font P, Simon S-P, Rednic S, Schiotis R, et al. Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis. Clin Rheumatol. 2011;30:691\u20135. Available from: \n                      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21221691\n                      \n                    .","journal-title":"Clin Rheumatol"},{"key":"55_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1186\/s13075-015-0873-1","volume":"17","author":"N Nigil Haroon","year":"2015","unstructured":"Nigil Haroon N, Szabo E, Raboud JM, Mcdonald-Blumer H, Fung L, Josse RG, et al. Alterations of bone mineral density, bone microarchitecture and strength in patients with ankylosing spondylitis: a cross-sectional study using high-resolution peripheral quantitative computerized tomography and finite element analysis. Arthritis Res Ther. 2015;17:377. Available from: \n                      http:\/\/arthritis-research.com\/content\/17\/1\/377\n                      \n                    .","journal-title":"Arthritis Res Ther"},{"key":"55_CR5","doi-asserted-by":"crossref","unstructured":"Van Der Weijden MAC, Claushuis TAM, Nazari T, Lems WF, Dijkmans BAC, Van Der Horst-Bruinsma IE. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: A systematic review. Clin Rheumatol. 2012;1529\u201335. This review showed that low BMD occurs early in AS, underscoring the importance of early screening.","DOI":"10.1007\/s10067-012-2018-0"},{"key":"55_CR6","doi-asserted-by":"crossref","unstructured":"Magrey MN, Lewis S, Asim Khan M. Utility of DXA scanning and Risk Factors for Osteoporosis in Ankylosing Spondylitis; A Prospective Study. Semin Arthritis Rheum. 2016;1\u20137. Available from: \n                      http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216000937","DOI":"10.1016\/j.semarthrit.2016.03.003"},{"key":"55_CR7","doi-asserted-by":"publisher","unstructured":"Ghozlani I, Ghazi M, Nouijai A, Mounach A, Rezqi A, Achemlal L, et al. Prevalence and risk factors of osteoporosis and vertebral fractures in patients with ankylosing spondylitis. Bone. 2009;44:772\u20136. Available from: doi:\n                      10.1016\/j.bone.2008.12.028\n                      \n                    .","DOI":"10.1016\/j.bone.2008.12.028"},{"key":"55_CR8","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3899\/jrheum.120316","volume":"39","author":"E Klingberg","year":"2012","unstructured":"Klingberg E, Geijer M, G\u00f6thlin J, Mellstr\u00f6m D, Lorentzon M, Hilme E, et al. Vertebral fractures in ankylosing spondylitis are associated with lower bone mineral density in both central and peripheral skeleton. J Rheumatol. 2012;39:12\u20133.","journal-title":"J Rheumatol"},{"key":"55_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00198-014-2939-3","volume":"26","author":"D Prieto-Alhambra","year":"2014","unstructured":"Prieto-Alhambra D, Mu\u00f1oz-Ortego J, De Vries F, Vosse D, Arden NK, Bowness P, et al. Ankylosing spondylitis confers substantially increased risk of clinical spine fractures: a nationwide case-control study. Osteoporos Int. 2014;26:85\u201391.","journal-title":"Osteoporos Int"},{"key":"55_CR10","unstructured":"Cooper C, Carbone L, Michet CJ, Atkinson EJ, O\u2019Fallon WM, Melton III LJ. Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol. 1994;21:1877\u201382. Available from: \n                      http:\/\/europepmc.org\/abstract\/MED\/7837154\n                      \n                    ."},{"key":"55_CR11","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1002\/jbmr.2217","volume":"29","author":"J Mu\u00f1oz-Ortego","year":"2014","unstructured":"Mu\u00f1oz-Ortego J, Vestergaard P, Rubio JB, Wordsworth P, Judge A, Javaid MK, et al. Ankylosing spondylitis is associated with an increased risk of vertebral and nonvertebral clinical fractures: a population-based cohort study. J Bone Miner Res. 2014;29:1770\u20136.","journal-title":"J Bone Miner Res"},{"key":"55_CR12","doi-asserted-by":"publisher","unstructured":"Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone. 2008;43:1115\u201321. Available from: doi:\n                      10.1016\/j.bone.2008.08.106\n                      \n                    .","DOI":"10.1016\/j.bone.2008.08.106"},{"key":"55_CR13","doi-asserted-by":"publisher","first-page":"356","DOI":"10.7326\/0003-4819-154-5-201103010-00307","volume":"154","author":"U.S. Preventive Services Task Force","year":"2011","unstructured":"U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. preventive services task force recommendation statement. Ann Intern Med. 2011;154:356\u201365.","journal-title":"Ann Intern Med"},{"key":"55_CR14","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA, Borgstrom F, De Laet C, Johansson H, Johnell O, Jonsson B, et al. Assessment of fracture risk. Osteoporos Int. 2005;16:581\u20139. Available from: \n                      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15616758\n                      \n                    .","journal-title":"Osteoporos Int"},{"key":"55_CR15","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25:2359\u201381.","journal-title":"Osteoporos Int"},{"key":"55_CR16","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1210\/jc.2011-3045","volume":"97","author":"NB Watts","year":"2012","unstructured":"Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:1802\u201322. Available from: \n                      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22675062\n                      \n                    .","journal-title":"J Clin Endocrinol Metab"},{"key":"55_CR17","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s10067-012-2018-0","volume":"31","author":"MAC Van Der Weijden","year":"2012","unstructured":"Van Der Weijden MAC, Claushuis TAM, Nazari T, Lems WF, Dijkmans BAC, Van Der Horst-Bruinsma IE. High prevalence of low bone mineral density in patients within 10 years of onset of ankylosing spondylitis: a systematic review. Clin Rheumatol. 2012;31:1529\u201335.","journal-title":"Clin Rheumatol"},{"key":"55_CR18","doi-asserted-by":"crossref","unstructured":"Kang KY, Ju JH, Park S-H, Kim H-Y. The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis. Rheumatology (Oxford). 2013;52:718\u201326. Available from: \n                      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23275389\n                      \n                    . This study demonstrated increased radiographic severity with TNFi treatment in addition to increased BMD. The TNFi treated cohort had more severe sacroiliitis at baseline which may partially explain increased radiographic severity.","DOI":"10.1093\/rheumatology\/kes364"},{"key":"55_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/ard.2007.084426","volume":"68","author":"S Visvanathan","year":"2009","unstructured":"Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, et al. Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis. 2009;68:175\u201382.","journal-title":"Ann Rheum Dis"},{"key":"55_CR20","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3899\/jrheum.150019","volume":"42","author":"H Li","year":"2015","unstructured":"Li H, Li Q, Chen X, Ji C, Gu J. Anti-tumor necrosis factor therapy increased spine and femoral neck bone mineral density of patients with active ankylosing spondylitis with low bone mineral density. J Rheumatol. 2015;42:1413\u20137.","journal-title":"J Rheumatol"},{"key":"55_CR21","first-page":"R108","volume":"14","author":"E Klingberg","year":"2012","unstructured":"Klingberg E, Lorentzon M, Mellstr\u00f6m D, Geijer M, G\u00f6thlin J, Hilme E, et al. Osteoporosis in ankylosing spondylitis\u2014prevalence, risk factors and methods of assessment. BioMed Central Ltd. 2012;14:R108. Available from: \n                      http:\/\/www.scopus.com\/inward\/record.url?eid=2-s2.0-84860605484&partnerID=tZOtx3y1\n                      \n                    .","journal-title":"BioMed Central Ltd"},{"key":"55_CR22","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00296-004-0515-4","volume":"26","author":"U Lange","year":"2005","unstructured":"Lange U, Kluge A, Strunk J, Teichmann J, Bachmann G. Ankylosing spondylitis and bone mineral density\u2014what is the ideal tool for measurement? Rheumatol Int. 2005;26:115\u201320.","journal-title":"Rheumatol Int"},{"key":"55_CR23","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/1471-2474-12-121","volume":"12","author":"M Korkosz","year":"2011","unstructured":"Korkosz M, G\u0105sowski J, Grzanka P, Gorczowski J, Pluskiewicz W, Jeka S, et al. Baseline new bone formation does not predict bone loss in ankylosing spondylitis as assessed by quantitative computed tomography (QCT): 10-year follow-up. BMC Musculoskelet Disord. 2011;12:121. Available from: \n                      http:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/1471-2474-12-121\n                      \n                    .","journal-title":"BMC Musculoskelet Disord"},{"key":"55_CR24","doi-asserted-by":"publisher","first-page":"R179","DOI":"10.1186\/ar4368","volume":"15","author":"E Klingberg","year":"2013","unstructured":"Klingberg E, Lorentzon M, G\u00f6thlin J, Mellstr\u00f6m D, Geijer M, Ohlsson C, et al. Bone microarchitecture in ankylosing spondylitis and the association with bone mineral density, fractures, and syndesmophytes. Arthritis Res Ther. 2013;15:R179. Available from: \n                      http:\/\/arthritis-research.com\/content\/15\/6\/R179\n                      \n                    .","journal-title":"Arthritis Res Ther"},{"key":"55_CR25","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Eastell R, Bruy\u00e8re O, Foldes A, Garnero P, Griesmacher A, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011;22:391\u2013420.","journal-title":"Osteoporos Int"},{"key":"55_CR26","doi-asserted-by":"crossref","unstructured":"Morris HA, Eastell R, Jorgesen NR, Cavalier E, Vasikaran S, Chubb SAP, et al. Clinical usefulness of bone turnover marker concentrations in osteoporosis. Clin Chim Acta. 2016; Available from: \n                      http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898116302819","DOI":"10.1016\/j.cca.2016.06.036"},{"key":"55_CR27","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1515\/CCLM.2011.602","volume":"49","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran S, Cooper C, Eastell R, Griesmacher A, Morris HA, Trenti T, et al. International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis. Clin Chem Lab Med. 2011;49:1271\u20134.","journal-title":"Clin Chem Lab Med"},{"key":"55_CR28","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00223-014-9842-y","volume":"94","author":"H Johansson","year":"2014","unstructured":"Johansson H, Od\u00e9n A, Kanis JA, McCloskey EV, Morris HA, Cooper C, et al. A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif. Tissue Int. 2014;94:560\u20137.","journal-title":"Tissue Int"},{"key":"55_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/03009742.2016.1152399","volume":"9742","author":"J Gamez-Nava","year":"2016","unstructured":"Gamez-Nava J, de la Cerda-Trujillo L, Vazquez-Villegas M, Cons-Molina F, Alcaraz-Lopez M, Zavaleta-Mu\u00f1iz S, et al. Association between bone turnover markers, clinical variables, spinal syndesmophytes and bone mineral density in Mexican patients with ankylosing. Scand J Rheumatol. 2016;9742:1\u201311. Available from: \n                      http:\/\/www.tandfonline.com\/doi\/full\/10.3109\/03009742.2016.1152399\n                      \n                    .","journal-title":"Scand J Rheumatol"},{"key":"55_CR30","doi-asserted-by":"crossref","unstructured":"Arends S, Spoorenberg A, Efde M, Bos R, Leijsma MK, Bootsma H, et al. Higher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: a cross-sectional analysis. PLoS One. 2014;9.","DOI":"10.1371\/journal.pone.0099685"},{"key":"55_CR31","doi-asserted-by":"publisher","first-page":"R98","DOI":"10.1186\/ar3823","volume":"14","author":"S Arends","year":"2012","unstructured":"Arends S, Spoorenberg A, Houtman PM, Leijsma MK, Bos R, Kallenberg CG, et al. The effect of three years of TNF\u03b1 blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther. 2012;14:R98. Available from: \n                      http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3446472&tool=pmcentrez&rendertype=abstract\n                      \n                    .","journal-title":"Arthritis Res Ther"},{"key":"55_CR32","unstructured":"Mirza F, Canalis E. Management of endocrine disease: secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015;1\u201352. Available from: \n                      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25971649"},{"key":"55_CR33","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s00198-015-3365-x","volume":"27","author":"B Zhou","year":"2016","unstructured":"Zhou B, Huang Y, Li H, Sun W, Liu J. Proton-pump inhibitors and risk of fractures: an update meta-analysis. Osteoporos Int. 2016;27:339\u201347.","journal-title":"Osteoporos Int"},{"key":"55_CR34","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.cca.2014.08.040","volume":"438","author":"G Cai","year":"2015","unstructured":"Cai G, Wang L, Fan D, Xin L, Liu L, Hu Y, et al. Vitamin D in ankylosing spondylitis: review and meta-analysis. Clin Chim Acta. 2015;438:316\u201322. Available from: \n                      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25199851\n                      \n                    .","journal-title":"Clin Chim Acta"},{"key":"55_CR35","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1093\/rheumatology\/keu042","volume":"53","author":"S Zhao","year":"2014","unstructured":"Zhao S, Duffield SJ, Moots RJ, Goodson NJ. Systematic review of association between vitamin D levels and susceptibility and disease activity of ankylosing spondylitis. Rheumatology. 2014;53:1595\u2013603. Available from: \n                      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24706990\n                      \n                    .","journal-title":"Rheumatology"},{"key":"55_CR36","doi-asserted-by":"publisher","unstructured":"Klingberg E, Oler\u00f6d G, Hammarsten O, Forsblad-d\u2019Elia H. The vitamin D status in ankylosing spondylitis in relation to intestinal inflammation, disease activity, and bone health: a cross-sectional study. Osteoporos Int. Osteoporosis International; 2016;1\u20137. Available from: doi:\n                      10.1007\/s00198-016-3489-7","DOI":"10.1007\/s00198-016-3489-7"},{"key":"55_CR37","unstructured":"Ross AC, Taylor CL, Yaktine AL, Del HB. Dietary reference intakes for calcium and vitamin D [Internet]. Instutute Med. 2011. Available from: \n                      http:\/\/www.nap.edu\/catalog\/13050\/dietary-reference-intakes-for-calcium-and-vitamin-d\n                      \n                    ."},{"key":"55_CR38","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1002\/art.39298","volume":"68","author":"MM Ward","year":"2016","unstructured":"Ward MM, Deodhar A, Akl EA, Lui A, Ermann J, Gensler LS, et al. American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol. 2016;68:282\u201398.","journal-title":"Arthritis Rheumatol"},{"key":"55_CR39","doi-asserted-by":"publisher","unstructured":"Redlich K, Smolen JS. Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov. 2012;11:234\u201350. Available from: doi:\n                      10.1038\/nrd3669\n                      \n                    .","DOI":"10.1038\/nrd3669"},{"key":"55_CR40","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s10067-006-0283-5","volume":"26","author":"A Bal","year":"2007","unstructured":"Bal A, Unlu E, Bahar G, Aydog E, Eksioglu E, Yorgancioglu R. Comparison of serum IL-1 beta, sIL-2R, IL-6, and TNF-alpha levels with disease activity parameters in ankylosing spondylitis. Clin Rheumatol. 2007;26:211\u20135. Available from: \n                      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16583185\n                      \n                    .","journal-title":"Clin Rheumatol"},{"key":"55_CR41","first-page":"855","volume":"35","author":"K Briot","year":"2008","unstructured":"Briot K, Gossec L, Kolta S, Dougados M, Roux C. Prospective assessment of body weight, body composition, and bone density changes in patients with spondyloarthropathy receiving anti-tumor necrosis factor-alpha treatment. J Rheumatol. 2008;35:855\u201361.","journal-title":"J Rheumatol"},{"key":"55_CR42","doi-asserted-by":"publisher","first-page":"758","DOI":"10.3899\/jrheum.150857","volume":"43","author":"MAC van der Weijden","year":"2016","unstructured":"van der Weijden MAC, van Denderen JC, Lems WF, Nurmohamed MT, Dijkmans BAC, van der Horst-Bruinsma IE. Etanercept increases bone mineral density in ankylosing spondylitis, but does not prevent vertebral fractures: results of a prospective observational cohort study. J Rheumatol. 2016;43:758\u201364. Available from: \n                      http:\/\/www.jrheum.org\/cgi\/doi\/10.3899\/jrheum.150857\n                      \n                    .","journal-title":"J Rheumatol"},{"key":"55_CR43","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.3899\/jrheum.121417","volume":"40","author":"A Durnez","year":"2013","unstructured":"Durnez A, Paternotte S, Fechtenbaum J, Landewe RB, Dougados M, Roux C, et al. Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study. J Rheumatol. 2013;40:1712\u20138. Available from: \n                      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23950191\n                      \n                    .","journal-title":"J Rheumatol"},{"key":"55_CR44","first-page":"191","volume":"34","author":"F Maas","year":"2016","unstructured":"Maas F, Spoorenberg A, Brouwer E, Schilder AM, Chaudhry RN, Wink F, et al. Radiographic vertebral fractures develop in patients with ankylosing spondylitis during 4 years of TNF-alpha blocking therapy. Clin Exp Rheumatol. 2016;34:191\u20139. This study demonstrated that increases in BMD conferred by TNF inhibitors did not translate into prevention of radiographic vertebral fractures.","journal-title":"Clin Exp Rheumatol"},{"key":"55_CR45","unstructured":"Alendronate Sodium Highlights Of Prescribing Information [Internet]. Whitehouse Station, NJ; Available from: \n                      https:\/\/www.merck.com\/product\/usa\/pi_circulars\/f\/fosamax\/fosamax_pi.pdf"},{"key":"55_CR46","unstructured":"Risedronate Sodium Highlights Of Prescribing Information [Internet]. Rockaway, NJ; Available from: \n                      http:\/\/www.allergan.com\/assets\/pdf\/actonel_pi"},{"key":"55_CR47","unstructured":"Ibandronate Highlights Of Prescribing Information [Internet]. South San Francisco, CA; Available from: \n                      http:\/\/www.gene.com\/download\/pdf\/boniva_tablets_prescribing.pdf"},{"key":"55_CR48","unstructured":"Zoledronic Acid Highlights Of Prescribing Information [Internet]. East Hanover, NJ; Available from: \n                      https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/reclast.pdf"},{"key":"55_CR49","doi-asserted-by":"crossref","unstructured":"Zhou J, Ma X, Wang T, Zhai S. Comparative efficacy of bisphosphonates in short-term fracture prevention for primary osteoporosis: a systematic review with network meta-analyses. Osteoporos Int. 2016;Available from: \n                      http:\/\/link.springer.com\/10.1007\/s00198-016-3654-z","DOI":"10.1007\/s00198-016-3654-z"},{"key":"55_CR50","first-page":"90","volume":"53","author":"O Viapiana","year":"2014","unstructured":"Viapiana O, Gatti D, Idolazzi L, Fracassi E, Adami S, Troplini S, et al. Bisphosphonates vs infliximab in ankylosing spondylitis treatment. Rheumatol (United Kingdom). 2014;53:90\u20134. This study showed that the amino-bisphosphonate, neridronate, was as effective as infliximab in reducing disease activity in AS and resulted in significantly higher BMD at the lumbar spine in comparison to infliximab after 6 months of therapy.","journal-title":"Rheumatol (United Kingdom)"},{"key":"55_CR51","doi-asserted-by":"publisher","first-page":"e18022","DOI":"10.5812\/ircmj.18022","volume":"16","author":"A Khabbazi","year":"2014","unstructured":"Khabbazi A, Noshad H, Gafarzadeh S, Hajialiloo M, Kolahi S. Alendronate effect on the prevention of bone loss in early stages of ankylosing spondylitis: a randomized, double-blind, placebo-controlled pilot study. Iran Red Crescent Med J. 2014;16:e18022. Available from: \n                      http:\/\/europepmc.org\/articles\/PMC4102986\/?report=abstract\n                      \n                    .","journal-title":"Iran Red Crescent Med J"},{"key":"55_CR52","doi-asserted-by":"crossref","unstructured":"Adler R A., Fuleihan GE-H, Bauer DC, Camacho PM, Clarke BL, Clines G a., et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2015;31:n\/a \u2013 n\/a. Available from: \n                      http:\/\/doi.wiley.com\/10.1002\/jbmr.2708","DOI":"10.1002\/jbmr.2708"},{"key":"55_CR53","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/(SICI)1096-9926(199908)60:2<68::AID-TERA10>3.0.CO;2-H","volume":"60","author":"N Patlas","year":"1999","unstructured":"Patlas N, Golomb G, Yaffe P, Pinto T, Breuer E, Ornoy A. Transplacental effects of bisphosphonates on fetal skeletal ossification and mineralization in rats. Teratology. 1999;60:68\u201373.","journal-title":"Teratology"},{"key":"55_CR54","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1006\/taap.1993.1148","volume":"121","author":"DH Minsker","year":"1993","unstructured":"Minsker DH, Manson JM, Peter CP. Effects of the bisphosphonate, alendronate, on parturition in the rat. Toxicol Appl Pharmacol. 1993;121:217\u201323.","journal-title":"Toxicol Appl Pharmacol"},{"key":"55_CR55","doi-asserted-by":"crossref","unstructured":"Lin JH. Bisphosphonates: A review of their pharmacokinetic properties. Bone. 1996;75\u201385.","DOI":"10.1016\/8756-3282(95)00445-9"},{"key":"55_CR56","unstructured":"Denosumab Highlights Of Prescribing Information [Internet]. Thousand Oaks, CA; Available from: \n                      http:\/\/pi.amgen.com\/united_states\/prolia\/prolia_pi.pdf"},{"key":"55_CR57","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1093\/rheumatology\/kel072","volume":"45","author":"H-R Kim","year":"2006","unstructured":"Kim H-R, Lee S-H, Kim H-Y, Kim H-Y. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford). 2006;45:1197\u2013200. Available from: \n                      http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16567356\n                      \n                    .","journal-title":"Rheumatology (Oxford)"},{"key":"55_CR58","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s10067-015-2913-2","volume":"34","author":"H Liang","year":"2015","unstructured":"Liang H, Zhang H, Ji H, Wang C. Effects of home-based exercise intervention on health-related quality of life for patients with ankylosing spondylitis: a meta-analysis. Clin Rheumatol. 2015;34:1737\u201344.","journal-title":"Clin Rheumatol"},{"key":"55_CR59","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s00296-014-2965-7","volume":"34","author":"T O\u2019Dwyer","year":"2014","unstructured":"O\u2019Dwyer T, O\u2019Shea F, Wilson F. Exercise therapy for spondyloarthritis: a systematic review. Rheumatol Int. 2014;34:887\u2013902.","journal-title":"Rheumatol Int"},{"key":"55_CR60","doi-asserted-by":"publisher","unstructured":"Millner JR, Barron JS, Beinke KM, Butterworth RH, Chasle BE, Dutton LJ, et al. Exercise for ankylosing spondylitis: an evidence-based consensus statement. Semin Arthritis Rheum. 2016;45:411\u201327. Available from: doi:\n                      10.1016\/j.semarthrit.2015.08.003\n                      \n                    .","DOI":"10.1016\/j.semarthrit.2015.08.003"},{"key":"55_CR61","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11657-016-0262-7","volume":"11","author":"JJ Armstrong","year":"2016","unstructured":"Armstrong JJ, Rodrigues IB, Wasiuta T, MacDermid JC. Quality assessment of osteoporosis clinical practice guidelines for physical activity and safe movement: an AGREE II appraisal. Arch Osteoporos. 2016;11:10\u20131.","journal-title":"Arch Osteoporos"}],"container-title":["Current Treatment Options in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40674-016-0055-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40674-016-0055-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40674-016-0055-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T23:50:29Z","timestamp":1589673029000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40674-016-0055-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,5]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["55"],"URL":"https:\/\/doi.org\/10.1007\/s40674-016-0055-6","relation":{},"ISSN":["2198-6002"],"issn-type":[{"value":"2198-6002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,5]]},"assertion":[{"value":"5 October 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"AMH declares no conflict of interest. GHL reports scientific advisory board with Janssen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number T32AR048522. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial Support and Sponsorship"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}